Loading
A dual-payload ADC is an ADC carrying two different poisons at once, so the tumour cannot escape by becoming resistant to one.
Programs from Sutro, Mersana, Tavotek/Adcoris (ACR335, TOP1 inhibitor + non-TOP1/non-tubulin, DAR 4+4, phase 1 in 2026), and others place two payloads with distinct mechanisms on one antibody. Rationale: TOP1-payload cross-resistance after T-DXd, sacituzumab, or Dato-DXd. Also 'dual-mechanism' ADCs pairing a cytotoxic with an immune agonist.
Orthogonal site-specific conjugation chemistries attach two payload classes at defined positions.
Query for this technology: (TITLE:"dual-payload antibody-drug conjugate" OR ABSTRACT:"dual-payload antibody-drug conjugate" OR TITLE:"dual payload ADC" OR ABSTRACT:"dual payload ADC" OR TITLE:"dual-payload ADC" OR ABSTRACT:"dual-payload ADC"). Results are unfiltered search hits about Dual-payload ADC, not a curated reading list.
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Metastatic triple-negative breast cancer and the tag frontier.
Shares Acquired resistance to every therapy, Antibody-drug conjugate (ADC) and the tag frontier.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Acquired resistance to every therapy, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Triple-negative breast cancer (TNBC) and the tag frontier.